Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02694965 · ClinicalTrials.gov registry record

Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma

A clinical trial, sponsored by Duke University.

Completed
Registry status
122
Enrollment target

NCT02694965 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 122 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02694965 has completed, sponsored by Duke University.

COMPLETED
Registry status
122 participants
Enrollment target

Study Summary

Purpose of the study: The investigators are proposing that melanomas which respond and develop eventual disease stability in response to checkpoint inhibitor immunotherapy undergo a genetic program promoting secondary resistance.

Interventions

  • OTHER observational

Trial Details

FieldValue
Enrollment Target 122 participants
Start Date 2016-01
Est. Completion 2023-06-07

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT02694965

The ClinicalTrials.gov registry entry for NCT02694965 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which observational is the first listed.

NCT02694965 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02694965 about?

NCT02694965 is a clinical study titled "Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma". Purpose of the study: The investigators are proposing that melanomas which respond and develop eventual disease stability in response to checkpoint inhibitor immunotherapy undergo a genetic program promoting secondary resistance.

What is the current status of trial NCT02694965?

This trial is currently completed. The enrollment target is 122 participants. The study started on 2016-01. Estimated completion is 2023-06-07.

What interventions are being tested in trial NCT02694965?

The interventions under investigation include: observational (OTHER).

Who is sponsoring clinical trial NCT02694965?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.